Burden of Niemann-Pick disease type C
3 evidence topics · 18 sources
Summary: definition, incidence, and prevalence
Niemann-Pick disease type C (NPC) is a progressive, life-limiting autosomal recessive neurovisceral lysosomal disorder caused by pathological variants in NPC1 or NPC2. At least 95% of cases are attributed to variants in NPC1 and the remainder to NPC2. Infantile-onset NPC refers to NPC in infants and children who first experience neurological symptoms before six years of age.
- Incidence: the estimated incidence is one case per 100 000 live births, and national expert center-based studies have reported annual incidence between 0.25 and 2.20 per 100 000 live births. One analysis determined a combined incidence of classical NPC of 1/89,229, or 1.12 affected patients per 100,000 conceptions, and suggested that there may be a late-onset NPC1 phenotype with an incidence on the order of 1/20,000 to 39,000. The FDA describes NPC as affecting an estimated 1 in 150,000 people.
- Prevalence in the United States: in a database representing 308 million unique individuals, 294 individuals had an NPC diagnosis, an identified prevalence of 0.95 per million; applying the distribution of NPC type and corresponding mortality estimates yielded an estimated 943 prevalent cases, or 2.9 per million, and an estimated 42 new cases per year.
- Infantile-onset fraction: the company states that approximately half of those living with NPC in the United States, 475 children, have infantile-onset NPC, and that approximately two-thirds of people with NPC in the United States remain undiagnosed. Among 168 participants with known neurological manifestations in a study of 203 participants from six European countries, 43 (24.2%) had early-infantile onset and 47 (26.4%) late-infantile onset. Among 422 NPC Registry participants with known age at neurological onset, 57 (13.5%) had early-infantile and 108 (25.6%) late-infantile onset. In pooled data from five national cohorts and the NPC Registry, the neurological onset group comprised 97 early infantile, 210 late infantile, 198 juvenile, and 163 adolescent/adult participants. Of 153 individuals diagnosed in France from 1990 to 2013, 32 (21%) had neurological onset before 2 years of age.
Summary: natural history, survival, and diagnostic delay
The age at onset of neurological symptoms predicts disease severity and life expectancy. The acute pre/perinatal form usually results in death before the age of 6 months.
- Age at death by onset category: in a United Kingdom cohort of 74 individuals, the mean age at death was 5.6 ± 2 years in the early-infantile group, 13.4 ± 6.7 years in the late infantile group, 25.9 ± 8.9 years in the juvenile onset group, and 33.7 ± 6.2 years in the adolescent/adult group. Fifty percent of patients with neurological onset before 2 years or between 2 and 11 years of age died within approximately 3 or 7 years of diagnosis, respectively. In a study of patients from six European countries, the median age at death was 5 years with the early infantile form (N = 17) and 8.8 years with the late infantile form (N = 17).
- Untreated early infantile onset: among untreated patients with early infantile onset in France, median survival was 4.42 years, and no patient in either the treated or the untreated group was alive beyond the age of 7 years 5 months.
- Cause of death: aspiration pneumonia preceded by dysphagia is the most common cause of death in individuals with neurological symptoms; two studies identified bronchopneumonia as the leading cause of death, accounting for approximately two-thirds of patients.
- Rate of progression: among 36 individuals aged 2 to 18 years, 30 of whom were receiving miglustat, the 5-domain NPC Clinical Severity Scale (NPCCSS) increased at an annualized rate of 1.5 points.
- Diagnostic delay: in the NPC Registry, the mean delay between first neurological symptoms and confirmed diagnosis was 2.5 years in early-infantile, 4.3 years in late-infantile, 6.2 years in juvenile, and 6.3 years in adolescent/adult patients. A separate analysis reported a mean delay of 4.1 years from the onset of neurological manifestations.
Summary: humanistic, caregiver, and economic burden
- Humanistic burden: in a survey of 49 caregivers and adult patients (patient age 13 months to 65 years; 37 in the United States and 12 in the United Kingdom), ambulation, swallowing, speech, fine motor skills, and cognition were the manifestations with the most impact on activities of daily living and health-related quality of life (HRQOL). Participants reported impact on the emotional (n = 26; 92.9%), physical (n = 24; 85.7%), social (n = 22; 78.6%), and psychological (n = 10; 35.7%) domains of patient HRQOL.
- Caregiver burden: 15 participants (53.6%) reported an impact of NPC on caregivers' HRQOL, and caregiver burden often required changes in lifestyle such as giving up work.
- Cost of illness: in a survey of 2007 costs with 18 Medical Resource Use questionnaires (29% response rate), the mean total annual cost per patient was 39,168 pounds (SD 50,315 pounds); direct medical costs accounted for 46%, direct non-medical costs for 24%, and indirect costs for 30%. The authors state that the estimates may be conservative because of the small sample size, low response rate, and potential recall bias.
- Access burden: in a survey of 79 respondents, 61% were unaware of Medicaid waivers, and delays and denials in obtaining essential medication, equipment, and services contributed to disease progression. Respondents reported high co-pays for miglustat, which is used off-label and costs approximately $58,000 per month.